Zobrazeno 1 - 10
of 401
pro vyhledávání: '"David F. Archer"'
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7667 (2024)
With the aim to shorten the time for diagnosis and accelerate access to correct management, a non-invasive diagnostic test for endometriosis was developed and validated. The IVD test combines an ELISA test kit to quantify CA125 and BDNF concentration
Externí odkaz:
https://doaj.org/article/32a47d7f4883464ca5f335dac88d1c6d
Autor:
David Hubacher, Courtney A. Schreiber, David K. Turok, Jeffrey T. Jensen, Mitchell D. Creinin, Kavita Nanda, Katharine O'Connell White, Ila Dayananda, Stephanie B. Teal, Pai-Lien Chen, Beatrice A. Chen, Alisa B. Goldberg, Jennifer L. Kerns, Clint Dart, Anita L. Nelson, Michael A. Thomas, David F. Archer, Jill E. Brown, Paula M. Castaño, Anne E. Burke, Bliss Kaneshiro, Diana L. Blithe
Publikováno v:
EClinicalMedicine, Vol 51, Iss , Pp 101554- (2022)
Summary: Background: The most widely used copper intrauterine device (IUD) in the world (the TCu380A), and the only product available in many countries, causes side effects and early removals for many users. These problems are exacerbated in nullipar
Externí odkaz:
https://doaj.org/article/db655b0464ca45c6b25f1bc9ab3dd9cb
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 15, p 4634 (2022)
Bleeding irregularities are one of the major reasons for discontinuation of oral contraceptives (OCs), and therefore clinicians need to set expectations during consultations. In this review we provide an overview of bleeding data of recently marketed
Externí odkaz:
https://doaj.org/article/708641d140f241eb86f2d3a86c2da36a
Publikováno v:
Therapeutic Advances in Reproductive Health, Vol 14 (2020)
While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly
Externí odkaz:
https://doaj.org/article/f1d50ede81344d98a88a55453a50e685
Autor:
Thomas Kimble, Anne E. Burke, Kurt T. Barnhart, David F. Archer, Enrico Colli, Carolyn L. Westhoff
Publikováno v:
Contraception: X, Vol 2, Iss , Pp 100020- (2020)
Objectives: To evaluate contraceptive effectiveness and safety of oral drospirenone 4 mg 24/4-day regimen in the United States. Study design: We performed a prospective, single-arm, multicenter phase 3 trial in sexually active women for up to thirtee
Externí odkaz:
https://doaj.org/article/e7d2ab3eda654be79ccd3959e498d13b
Publikováno v:
Contraception and Reproductive Medicine, Vol 2, Iss 1, Pp 1-8 (2017)
Abstract Heavy menstrual bleeding (HMB) is a common gynecological problem that has a significant impact on a woman’s quality of life and the activities of daily living. Due to the difficulty in accurately describing menstrual bleeding abnormalities
Externí odkaz:
https://doaj.org/article/bc4d5c8071ae4778906fbe3f200c1e60
Publikováno v:
Gerontology and Geriatric Medicine, Vol 1 (2015)
Objective: To examine whether serum concentrations of C-reactive protein (CRP) and fibrinogen were associated with total score on a validated 12-item physical functioning scale and whether the magnitude and direction of these associations differed ac
Externí odkaz:
https://doaj.org/article/f6f812c29bcc4275bdd8176bea605713
Publikováno v:
Revista Colombiana de Obstetricia y Ginecología, Vol 48, Iss 3 (1997)
Objetivo: Investigar la severidad y localización del dolor pélvico asociado con endometriosis durante los años de vida reproductiva y evaluar la asociación entre estos parámetros de dolor y el estado de la enfermedad. Diseño: Estudio históric
Externí odkaz:
https://doaj.org/article/b7ba7030a8d2494ea87e88326cc94c6c
Publikováno v:
Gynecological Endocrinology. 38:891-910
Autor:
Carolyn L, Westhoff, David F, Archer, Kurt, Barnhart, Philip, Darney, Melissa, Gilliam, Jeffrey, Jensen, Anita, Nelson, Stephanie, Teal, Michael, Thomas, Jack, Hu, Jill, Brown, Diana L, Blithe
Publikováno v:
Contraception. 112:54-60
To describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days.This multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 cycle regimen of 5 mg for 24 days follo